The earnings transcript for Ceradyne reveals a mixed picture, with record annual sales but reduced guidance for 2008 due to delays in military contracts and a reduced forecast for body armor. The company's management expects a gap in ESAPI deliveries, which will impact revenue. However, they are optimistic about growth in non-defense markets, such as solar ceramics, and are expanding their manufacturing capacity in China and Germany. The company is also pursuing strategic acquisitions and has a strong cash position, which could be used for stock buybacks or acquisitions. Considering these factors, the stock is likely to face short-term pressure due to the reduced guidance and uncertainties around key defense contracts.
[-1]